Skip to main content
Equibles
PTHS logo

PTHS · Pelthos Therapeutics Inc.

Track PTHS — free

Use PTHS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$24.35 -0.01 (-0.04%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — cleared May 14, 2026

The latest filing states the doubt was alleviated.

“in prior periods, management disclosed substantial doubt about the Company's ability to continue as a going concern. The conditions and events that previously raised substantial doubt have been alleviated by management's plans and actions.”
View the 10-Q filed May 14, 2026
Market Cap
$93.22M
Shares
3.83M

PTHS metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$24.35
Market cap
$93.22M

Price action

19 metrics
Price change (1W)
-1.5%
Price change (30D)
-16.0%
Price change (3M)
-4.7%
Price change (6M)
+5.3%
Price change (YTD)
-21.5%
Price change (1Y)
-25.1%
Trailing year
Price change (5Y)
—
52-week high
$37.42
52-week low
$18.19
Change from 52-week high
-34.9%
Change from 52-week low
+33.9%
Annualized volatility
79.4%
Beta
0.3
RSI (14D)
41.0
Price vs SMA 50
-9.0%
Price vs SMA 200
-4.5%
Avg volume (3M)
56,365
Relative volume
0.3
Average dollar volume
$1.52M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.2×
reciprocal yield 46.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-92.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
78.6%
Operating margin
-133.4%
Trailing 12 months
Net margin
-199.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$57.78M
Net income (TTM)
−$86.39M
Trailing 12 months
Diluted EPS (TTM)
$-28.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-33.36

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$43.30M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+442.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-62.9%
Debt / equity
—
Current ratio
2.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
-7.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$24.19M
Latest balance sheet
Cash & equivalents
$24.19M
Total assets
$137.36M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$42.30M
Capital expenditures (TTM)
$295,000
R&D (TTM)
$1.30M
SG&A (TTM)
$86.87M
Stock compensation (TTM)
$9.23M
R&D / revenue
3.0%
Stock compensation / revenue
21.3%

Ownership (13F)

3 metrics
13F filers
24
13F filer change QoQ
+7
Institutional ownership
34.6%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 1.2 days to cover
Days to cover
1.2d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
$936,315
Insider-sentiment score
89 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1919246 CUSIP 171126204 13F (30d) 18 filings 18 filers Visit website Investor relations